李氏大藥廠(00950.HK)正式公佈ANFIBATIDE安全性及抗血栓功效I期臨試結果
格隆匯6月7日丨李氏大藥廠(00950.HK)發佈公吿,評估安菲博肽在體外、人體血液離體以及在健康人體受試者體內注射和輸液後的抗血栓功效及安全性的I期臨牀試驗(clinicaltrials.gov註冊編號:NCT01588132)已經完成,其主要研究結果已於2021年6月3日在《科學報吿》上發表,文章標題為《靶向人血小板GPIbα的蛇毒源抗血栓劑安菲博肽的體外評估及I期隨機臨牀試驗*》(In vitro assessment and phase I randomized clinical trial of Anfibatide a snake venom derived anti-thrombotic agent targeting human platelet GPIbα)。發表在期刊中的資料顯示,安菲博肽可能是一種靶向血小板GPIbα的安全和有效的抗血栓治療劑,並且值得進一步研究。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.